Metastasising Fibroblasts Show an HDAC6-Dependent Increase in Migration Speed and Loss of Directionality Linked to Major Changes in the Vimentin Interactome.
Actins
/ metabolism
Animals
Cell Adhesion
/ physiology
Cell Movement
/ physiology
Cell Shape
/ physiology
Cell-Matrix Junctions
/ metabolism
Cells, Cultured
Collagen
/ metabolism
Cytoskeleton
/ metabolism
Fibroblasts
/ metabolism
Histone Deacetylase 6
/ metabolism
Humans
Mice
Oncogenes
/ physiology
Vimentin
/ metabolism
cell migration
fibroblasts
genome-wide mass spectrometry
histone deacetylase 6
metastasis
oncogenes
stimulated emission depletion microscopy
vimentin
vimentin interactome
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
10 Feb 2022
10 Feb 2022
Historique:
received:
30
11
2021
revised:
04
02
2022
accepted:
07
02
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Metastasising cells express the intermediate filament protein vimentin, which is used to diagnose invasive tumours in the clinic. We aimed to clarify how vimentin regulates the motility of metastasising fibroblasts. STED super-resolution microscopy, live-cell imaging and quantitative proteomics revealed that oncogene-expressing and metastasising fibroblasts show a less-elongated cell shape, reduced cell spreading, increased cell migration speed, reduced directionality, and stronger coupling between these migration parameters compared to normal control cells. In total, we identified and compared 555 proteins in the vimentin interactome. In metastasising cells, the levels of keratin 18 and Rab5C were increased, while those of actin and collagen were decreased. Inhibition of HDAC6 reversed the shape, spreading and migration phenotypes of metastasising cells back to normal. Inhibition of HDAC6 also decreased the levels of talin 1, tropomyosin, Rab GDI β, collagen and emilin 1 in the vimentin interactome, and partially reversed the nanoscale vimentin organisation in oncogene-expressing cells. These findings describe the changes in the vimentin interactome and nanoscale distribution that accompany the defective cell shape, spreading and migration of metastasising cells. These results support the hypothesis that oncogenes can act through HDAC6 to regulate the vimentin binding of the cytoskeletal and cell-extracellular matrix adhesion components that contribute to the defective motility of metastasising cells.
Identifiants
pubmed: 35216078
pii: ijms23041961
doi: 10.3390/ijms23041961
pmc: PMC8880509
pii:
doi:
Substances chimiques
Actins
0
VIM protein, human
0
Vimentin
0
Collagen
9007-34-5
HDAC6 protein, human
EC 3.5.1.98
Histone Deacetylase 6
EC 3.5.1.98
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Sci Rep. 2016 Apr 13;6:24389
pubmed: 27072292
Methods Cell Biol. 2004;78:3-24
pubmed: 15646613
Cells. 2017 Jan 22;6(1):
pubmed: 28117759
Proteomics. 2008 Jan;8(2):279-88
pubmed: 18203277
Cell. 2015 Apr 9;161(2):374-86
pubmed: 25799384
Neoplasia. 2005 Jun;7(6):585-93
pubmed: 16036109
J Proteome Res. 2020 Jan 3;19(1):204-211
pubmed: 31657565
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6853-8
pubmed: 23569271
J Med Chem. 2021 Feb 11;64(3):1362-1391
pubmed: 33523672
Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4320-7
pubmed: 27466403
Nat Cell Biol. 2004 Oct;6(10):977-83
pubmed: 15448700
Methods. 2017 Feb 15;115:80-90
pubmed: 27713081
Cytometry A. 2013 Sep;83(9):855-65
pubmed: 23657948
Clin Cancer Res. 2018 Jan 15;24(2):420-432
pubmed: 29208669
Anticancer Res. 2008 Jan-Feb;28(1A):327-34
pubmed: 18383865
J Cell Biol. 1971 Dec;51(3):752-62
pubmed: 4942774
J Cell Sci. 2021 Mar 29;134(6):
pubmed: 33558312
J Biol Chem. 2004 Apr 2;279(14):13640-4
pubmed: 14732703
Cell Adh Migr. 2018 May 4;12(3):185-194
pubmed: 29099266
Mol Biol Cell. 2011 Apr 15;22(8):1274-89
pubmed: 21346197
Mol Cell Biol. 2011 Sep;31(18):3773-89
pubmed: 21746880
Cancer Lett. 2009 May 8;277(1):8-21
pubmed: 18824292
Oncogene. 2011 Jan 27;30(4):457-70
pubmed: 20856200
Nature. 1999 Jul 29;400(6743):464-8
pubmed: 10440377
Cell Syst. 2016 Nov 23;3(5):500-501
pubmed: 27883892
Am J Pathol. 1997 Feb;150(2):483-95
pubmed: 9033265
Oncotarget. 2015 Jun 30;6(18):15966-83
pubmed: 25965826
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
PLoS One. 2014 Feb 28;9(2):e90384
pubmed: 24587345
Mol Biol Cell. 2013 Jan;24(1):21-30
pubmed: 23115305
Phys Rev Lett. 2020 Dec 31;125(26):268102
pubmed: 33449749
J Exp Med. 2010 Oct 25;207(11):2421-37
pubmed: 20937704
Cell Motil Cytoskeleton. 2008 Aug;65(8):614-25
pubmed: 18553359
Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1515-20
pubmed: 24474778
Front Cell Dev Biol. 2017 Sep 14;5:81
pubmed: 28959689
Oncogene. 2011 Mar 24;30(12):1436-48
pubmed: 21057535
PLoS One. 2012;7(8):e42989
pubmed: 22900077
Cell Stem Cell. 2020 Apr 2;26(4):558-568.e9
pubmed: 32109376
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
FEBS J. 2018 May;285(9):1635-1652
pubmed: 29542240
J Hematol Oncol. 2018 Sep 3;11(1):111
pubmed: 30176876
Nature. 2011 May 19;473(7347):337-42
pubmed: 21593866
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1413-E1421
pubmed: 28174275
F1000Res. 2018 Nov 15;7:
pubmed: 30505430
J Cell Sci. 1998 Jul;111 ( Pt 13):1897-907
pubmed: 9625752
Mol Cell Proteomics. 2006 Dec;5(12):2211-27
pubmed: 16959763
Cancer Biomark. 2012;12(2):49-64
pubmed: 23396250
Curr Opin Cell Biol. 2020 Oct;66:79-88
pubmed: 32623234
Protein Sci. 2021 Jan;30(1):187-200
pubmed: 33070389